A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study
W. Kenneth Washburn, Lewis W. Teperman, Thomas G. Heffron, David D. Douglas, Steven Gay, Eliezer Katz, Goran B.G. Klintmalm – 2 February 2006 – This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3‐dose regimen of daclizumab in de novo hepatitis C liver transplant recipients.